Thesis
The analysts at Zacks have lifted their earnings estimates for Pfizer to $0.90 per share, signaling a potentially positive trend for the stock. With a moderate buy rating and a decent dividend yield, I believe PFE has room to grow in the upcoming quarters, making it viable for a swing trade.